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Abstract
Objective To estimate the risk of self-harm in people with epilepsy and identify factors which influence this risk.
Methods We identified people with incident epilepsy in the Clinical Practice Research Datalink, linked to hospitalization 
and mortality data, in England (01/01/1998–03/31/2014). In Phase 1, we estimated risk of self-harm among people with 
epilepsy, versus those without, in a matched cohort study using a stratified Cox proportional hazards model. In Phase 2, we 
delineated a nested case–control study from the incident epilepsy cohort. People who had self-harmed (cases) were matched 
with up to 20 controls. From conditional logistic regression models, we estimated relative risk of self-harm associated with 
mental and physical illness comorbidity, contact with healthcare services and antiepileptic drug (AED) use.
Results Phase 1 included 11,690 people with epilepsy and 215,569 individuals without. We observed an adjusted hazard 
ratio of 5.31 (95% CI 4.08–6.89) for self-harm in the first year following epilepsy diagnosis and 3.31 (95% CI 2.85–3.84) in 
subsequent years. In Phase 2, there were 273 cases and 3790 controls. Elevated self-harm risk was associated with mental 
illness (OR 4.08, 95% CI 3.06–5.42), multiple general practitioner consultations, treatment with two AEDs versus mono-
therapy (OR 1.84, 95% CI 1.33–2.55) and AED treatment augmentation (OR 2.12, 95% CI 1.38–3.26).
Conclusion People with epilepsy have elevated self-harm risk, especially in the first year following diagnosis. Clinicians 
should adequately monitor these individuals and be especially vigilant to self-harm risk in people with epilepsy and comorbid 
mental illness, frequent healthcare service contact, those taking multiple AEDs and during treatment augmentation.
Keywords Epilepsy · Self-harm/self harm · Case–control · Cohort · Epidemiology
Introduction
People with epilepsy are twice as likely to die by suicide 
compared to those without epilepsy [1]. Nonfatal self-harm, 
defined as any type of intentional self-injury or self-poison-
ing [2], may lie on the causal pathway between epilepsy and 
suicide. There are multiple motivations for engaging in self-
harm, ranging from suicide attempt to emotional regulation 
without suicidal ideation [2]. Regardless of intent, self-harm 
is the strongest predictor of suicide [3].
Risk of hospitalization for self-harm in people with epi-
lepsy has been estimated in two studies [4, 5]. Singhal et al. 
reported a relative risk of 3.9 (95% CI 3.8–4.1) for self-
harm in the year following hospitalization for epilepsy and 
2.6 (95% CI 2.5–2.7) in subsequent years [4]. Meyer et al. 
estimated the hospital self-harm presentation rate in people 
with epilepsy to be 2.04 (95% CI 1.85–2.25) times that of 
the comparison group [5]. Meyer et al. identified epilepsy 
diagnosis from the self-harm reporting form, as part of a 
multi-centre study, and confirmed with review of medical 
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notes [5]. Singhal et al. identified people with epilepsy 
from recorded hospital admission or day case contact due 
to epilepsy [4]. It is possible, therefore, that this may have 
included only individuals with the most severe or poorly 
managed epilepsy, which resulted in hospital presentation. 
Both studies required individuals to be hospitalized for the 
self-harm event, thus do not include those who presented in 
the community for self-harm. A previous study conducted in 
a UK primary care dataset estimated an odds ratio for self-
harm of (2.35, 95% CI 1.67–3.29) for people with epilepsy 
compared to those without [6]. Self-harm cases were defined 
from those reported in primary care only, as this study was 
conducted before it was possible to link this dataset with 
hospital records. It is not known whether this magnitude of 
increased risk for self-harm is observed in a primary care 
patient cohort when linked to hospital reports of self-harm 
and national mortality records.
The World Health Organization (WHO) recommends that 
people with epilepsy should be asked about self-harming 
thoughts and behaviours in certain, specific circumstances 
[7]. However, there may be additional factors that could alert 
clinicians to instigate this discussion. To our knowledge, the 
factors that influence someone with epilepsy to self-harm 
have not been identified.
We, therefore, aimed to: (1) estimate self-harm risk in 
persons with epilepsy versus those without; and (2) identify 
risk factors for self-harm among individuals with epilepsy.
Methods
Setting
We extracted an incident epilepsy cohort from the Clini-
cal Practice Research Datalink (CPRD), linked to Hospital 
Episode Statistics (HES) and Office for National Statistics 
(ONS) mortality data. The CPRD is a primary care dataset 
that contains routinely collected electronic health records 
capturing information on patient demographics, diagnoses 
and treatments in general practice. It has been shown to be 
representative of the UK population [8]. All of the linked 
general practices were located in England, representing 75% 
of all English practices included in the CPRD at the time of 
data extraction. We used the linked subset of the July 2015 
version containing 7,378,852 individuals from 378 general 
practices with data deemed to be of sufficient quality for 
conducting research. HES contains hospital inpatient dis-
charge dates and diagnoses, and ONS mortality data include 
date and cause of death.
The study was approved by the Independent Scientific 
Advisory Committee (protocol 17_063R) of the CPRD. 
Informed consent is not required for studies that use 
anonymized data from the CPRD.
Study population: incident epilepsy cohort
From the CPRD, we extracted the incident epilepsy cohort 
that formed the basis for both Phase 1 and Phase 2. The 
study observation period was 01/01/1998–31/03/2014 to 
correspond with linkage availability. We used our previ-
ously published definition to identify people with epilepsy 
[1] which requires a diagnostic code for epilepsy and an 
associated prescription for an antiepileptic drug (AED) 
[9, 10]. We defined the epilepsy index date as the latest of 
the epilepsy diagnosis date and AED prescription in the 6 
months prior, or 1 month after diagnosis. We restricted to 
the incident epilepsy cohort by mandating at least 12 months 
registration prior to epilepsy index date, and no prior epi-
lepsy diagnosis in this look-back period. This minimized the 
risk of ‘prevalent-user bias’, whereby the timing of epilepsy 
onset could confound the relationship with self-harm risk 
[11]. We required individuals to be without history of self-
harm in the look-back. We restricted the cohort to persons 
aged ten or older, as this is the minimum age at which the 
WHO recommend that clinicians should discuss self-harm 
[7]. This threshold also aligns with previously published 
studies, because self-harm intent is particularly difficult to 
discern below age ten [12].
Phase 1: matched cohort study
We matched each person with incident epilepsy to up to 
20 individuals without epilepsy on gender, year of birth 
(± 2 years) and general practice. Individuals sampled for 
the comparison cohort had not received a diagnostic code 
for epilepsy or self-harm in the look-back period, and had 
been registered for at least 12 months at the practice. Indi-
viduals were followed up until the earliest date of: first 
self-harm event, death, patient transferred out of practice, 
latest date of data collection from the practice, or end of 
the study’s observation period.
Phase 2: nested case–control study
From the cohort of people with incident epilepsy, we identi-
fied first recorded cases of self-harm during the study win-
dow—the self-harm case date. We matched these cases to up 
to 20 control individuals from within the incident epilepsy 
cohort, without history of self-harm on the self-harm case 
date, using incidence-density sampling [13]. We matched 
cases to controls on gender, year of birth (± 2 years) and 
timing of incident epilepsy diagnosis (± 1 year), because 
these variables may confound the relationship between the 
exposures investigated and self-harm risk [14].
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Outcomes
We included both fatal (suicide) and nonfatal self-harm in 
our definition. We identified self-harm from primary care 
records using clinician-verified Read codes [15] and from 
HES using the following ICD-10 codes: X60-84, Y87.0 
and Y87.2. We used these same codes to identify suicide 
from ONS mortality data, with the addition of Y10-34 
(excluding Y33.9) [16]. These codes represent undeter-
mined intent, which is included in the ONS definition of 
suicide [17]. As this conclusion is assigned by a coroner 
in the UK, it is not appropriate to apply the same codes to 
nonfatal self-harm.
In Phase 2, we investigated multiple exposures. We 
identified level of deprivation by quintiles of Index of 
Multiple Deprivation (IMD-2010), and compared to the 
least deprived quintile (1st quintile). We identified men-
tal illness diagnoses (alcohol misuse, anxiety disorder, 
bipolar disorder, depression, eating disorder, personal-
ity disorder and schizophrenia) from primary care data 
and HES using previously published codes [15, 18] that 
were recorded prior to self-harm case date. We developed 
a code list for substance misuse that was independently 
verified by two general practitioners (GPs) and is avail-
able at http://www.clini calco des.org [19]. We identified 
referrals to psychiatric services in the year prior to self-
harm case date from Family Health Services Authority and 
National Health Service speciality fields in the CPRD [20]. 
Contact with healthcare services was measured by number 
of face-to-face consultations with the GP and number of 
hospitalizations for any reason, in the year prior to self-
harm case date. Physical illness comorbidity was meas-
ured by assignment of a Charlson index score using Read 
codes from the CPRD [21] and ICD-10 codes from HES. 
The Charlson index is a measure of comorbidity, based 
on 1-year mortality risk derived from 17 comorbidities 
[21]. We measured AED utilization in two ways. First, 
we counted the number of AED types that the person was 
exposed to in the 90 days prior to self-harm case date and 
compared this to AED monotherapy. Second, we deter-
mined if there had been augmentation of AED treatment in 
the 6 months prior to self-harm index data. Due to the rec-
ommendation of slow withdrawal of AEDs when changing 
therapy [22], we defined augmentation as persistence of 
two AEDs 90 days after the introduction of the additional 
AED.
Statistical analysis
In Phase 1, we estimated the relative risk of self-harm in 
the incident epilepsy versus comparison cohorts using a 
stratified Cox proportional hazards model. We adjusted for 
level of deprivation because both epilepsy [23] and self-
harm [15] are independently associated with higher levels 
of deprivation, which may confound any observed associa-
tions. We assessed the proportionality assumption using 
a formal test that compared Schoenfeld residuals, with a 
p value < 0.05 indicating non-proportionality [24], and by 
graphical inspection. We reported baseline characteristics 
as numerical and percentage frequencies and medians, and 
estimated prevalence ratios for pre-existing mental illness 
diagnoses and types of prescribed psychotropic medica-
tion. In Phase 2, we used conditional logistic regression 
to estimated exposure odds ratios to indicate relative risk 
of self-harm associated with the following exposures: 
(1) level of deprivation; (2) mental illness; (3) referral to 
psychiatric services; (4) contact with healthcare services; 
(5) physical illness comorbidity; and (6) AED utilization. 
Data analysis for both phases was undertaken using Stata, 
version 13 (StataCorp, College Station, TX, USA).
Results
Phase 1: matched cohort study
We matched 11,690 people with incident epilepsy (median 
age 53, IQR 30–72; 52% male) to 215,569 persons with-
out epilepsy. Compared to the matched cohort, the epilepsy 
cohort was more deprived and more likely to have been 
diagnosed with any mental illness, treated with psychotropic 
medication or opioids (Table 1). The median follow-up times 
were 3.6 years (IQR 1.3–7.2) and 4.7 years (IQR 2.0–8.3) for 
the epilepsy and comparison cohorts, respectively.
There were 273 first self-harm events in the epilepsy 
cohort and 1547 in the comparison cohort. The overall inci-
dence rates for first self-harm event (Table 2) were greater 
in the epilepsy cohort (5.0 per 1000 person-years, 95% CI 
4.4–5.6) than in the comparison cohort (1.3 per 1000 person-
years, 95% CI 1.3–1.4). The proportionality assumption for 
the stratified Cox proportional hazards model did not hold 
(p = 0.007); therefore, we divided follow-up time to first year 
after diagnosis and subsequent years. There was an excess 
risk of self-harm during the first year of follow-up (depri-
vation-adjusted HR 5.31, 95% CI 4.08–6.89) compared to 
subsequent years (deprivation-adjusted HR 3.31, 95% CI 
2.85–3.84), although elevated risk persisted throughout the 
follow-up period.
Phase 2: nested case–control study
Within the epilepsy cohort we identified 273 individuals 
with a first self-harm event (cases) and matched them to 
3790 control patients with epilepsy and without history of 
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self-harm on the self-harm case date (Table 3). The median 
age was 34 years (IQR 20–46) and 43% were male. The 
median time since epilepsy diagnosis was 2.6 years (IQR 
0.9–4.6) for persons who had self-harmed and 2.2 years 
(IQR 1.0–3.9) for control patients. Individuals living in the 
most deprived areas had an elevated self-harm risk com-
pared to those living in the least deprived localities (5th 
quintile: OR 2.22, 95% CI 1.44–3.42, 4th quintile: OR 1.75, 
95%CI 1.11–2.75), but there was no evidence of increased 
risk associated with other quintiles of deprivation.
There was no difference in self-harm risk associated 
with a Charlson comorbidity index score of 1 or 2–3, but 
an increased risk was evident when the score was 4 or more 
(OR 2.91, 95% CI 1.75–4.82). 65.9% of cases and 35.6% of 
controls had a history of mental illness. Having one or more 
mental illness diagnoses increased self-harm risk compared 
to having no such diagnoses (OR 4.08, 95% CI 3.06–5.42) 
and this risk increased markedly among individuals who had 
received three or more mental illness diagnoses (OR 15.36, 
95% CI 10.03–23.51).
All mental illnesses examined were associated with an 
increased self-harm risk, but the magnitude varied across 
the diagnostic categories. Depression was the most common 
diagnosis and was associated with approximately a fourfold 
elevation in self-harm risk (OR 3.92, 95% CI 2.94–5.22). 
In a post hoc sensitivity analysis, we included depression 
symptom codes as well as diagnoses in the definition of 
depression. This did not alter the estimated risk (OR 4.03, 
95%CI 3.04–5.33).
In the 12 months prior to self-harm case date, 12.8% of 
cases and 3.8% of controls were referred to specialist psychi-
atric services (OR 3.65, 95% CI 2.45–5.44). In the same time-
frame, 45.8% of self-harm cases and 29.1% of controls were 
hospitalized at least once for any reason (OR 2.12, 95% CI 
1.64–2.76). The median number of face-to-face consultations 
with a GP in the 12 months preceding the self-harm case date 
Table 1  Prevalence of 
diagnosed mental illnesses 
and psychotropic medication 
prescribing at baseline
a p < 0.05




Prevalence ratios (95% CI)
Previous diagnoses
 Alcohol  misusea 596 (5.1%) 2433 (1.1%) 4.53 (4.14–4.95)
 Anxiety  disordersa 2053 (17.6%) 26,405 (12.3%) 1.43 (1.37–1.50)
 Bipolar  disordera 87 (0.7%) 718 (0.3%) 2.25 (1.80–2.81)
 Depressiona 2475 (21.2%) 30,084 (14.0%) 1.52 (1.45–1.58)
 Eating  disordersa 138 (1.2%) 1337 (0.6%) 1.88 (1.58–2.24)
 Personality  disordersa 83 (0.7%) 567 (0.3%) 2.72 (2.16–3.42)
 Schizophrenia-spectrum 
 disordersa
238 (2.0%) 1420 (0.7%) 3.09 (2.69–3.55)
 Substance  misusea 660 (5.7%) 2316 (1.1%) 5.21 (4.77–5.68)
Prior prescription
 Antidepressanta 3952 (33.8%) 46,714 (21.7%) 1.56 (1.51–1.61)
 Antipsychotica 2318 (19.8%) 27,165 (12.6%) 1.59 (1.52–1.66)
 Anxiolytic/hypnotica 3527 (30.1%) 36,609 (17.0%) 1.50 (1.04–2.02)
 Lithiuma 38 (0.3%) 491 (0.2%) 1.79 (1.73–1.85)
 Opioida 5137 (43.9%) 76,516 (35.5%) 1.25 (1.21–1.28)
Table 2  Incident rates and relative risks of first self-harm event
Number of self-harm events and incidence rates of self-harm per 1000 person-years, in epilepsy and comparison cohorts. Unadjusted hazard 
ratios and hazard ratios adjusted for level of deprivation indicate relative risk of self-harm
First self-harm Epilepsy (n = 11,690, 
PY = 54,692)
Comparison cohort 
(n = 215,569, PY = 1,170,253)
Unadjusted HR (95% CI) Deprivation-
adjusted HR 




 Any time during follow-up 273 5.0 (4.4–5.6) 1547 1.3 (1.3–1.4) 3.82 (3.36–4.34) 3.67 (3.22–4.17)
 0–1 year of follow-up 72 6.9 (5.4–8.7) 253 1.3 (1.1–1.4) 5.50 (4.24–7.15) 5.31 (4.08–6.89)
 After 1 year of follow-up 201 4.5 (3.9–5.2) 1294 1.3 (1.3–1.4) 3.45 (2.97-4.00) 3.31 (2.85–3.84)
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was nine (IQR 5–15) for cases and six (IQR 3–11) for controls. 
Compared to individuals who had 0–4 consultations in the 
previous year, individuals who had five or more consultations 
were at a two- to fivefold increased self-harm risk.
In the 90 days prior to self-harm case date, compared to 
individuals who were prescribed a single AED, those pre-
scribed no AED (OR 1.47, 95% CI 1.01–2.12), two (OR 
1.84, 95% CI 1.33–2.55) or three or more AEDs (OR 2.44, 
95% CI 1.51–3.94) were at an increased risk of self-harm 
(Table 4). Augmentation of AED treatment in the prior 6 
months was associated with a twofold increased risk of 
self-harm compared to no augmentation (OR 2.12, 95% CI 
1.38–3.26).
Discussion
In a large population-based cohort study, we found that peo-
ple with epilepsy have an elevated self-harm risk compared 
to those without the condition. There was a fivefold elevation 
in risk in the first year following diagnosis and a threefold 
increased risk persisting beyond this first year. Among peo-
ple with epilepsy, those most likely to self-harm included 
people with comorbid mental illness diagnoses, previous 
Table 3  Exposure odds ratios 
indicating risk factors for self-
harm in the epilepsy cohort
Mental illness diagnoses and diagnoses included in the Charlson comorbidity index were included if ever 
recorded prior to self-harm case date
Risk factors Cases (n = 273) Controls (n = 3790) Odds ratio (95% CI)
Level of deprivation
 1 (least deprived) 30 (11.0%) 689 (18.2%) 1 (ref)
 2 51 (18.7%) 804 (21.2%) 1.43 (0.90–2.28)
 3 47 (17.2%) 653 (17.2%) 1.61 (1.00-2.59)
 4 59 (21.6%) 765 (20.2%) 1.75 (1.11–2.75)
 5 86 (31.5%) 869 (22.9%) 2.22 (1.44–3.42)
 missing 0 10 (0.3%) N/A
Any mental illness diagnosis 180 (65.9%) 1350 (35.6%) 4.08 (3.06–5.42)
Number of mental illness diagnoses
 0 93 (34.1%) 2440 (64.4%) 1 (ref)
 1 81 (29.7%) 764 (20.2%) 3.24 (2.34–4.50)
 2 40 (14.6%) 445 (11.7%) 3.07 (2.03–4.66)
 3 or more 59 (21.6%) 141 (3.7%) 15.36 (10.03–23.51)
Prior history of diagnoses
 Alcohol misuse 54 (19.8%) 186 (4.9%) 5.31 (3.70–7.94)
 Anxiety disorders 97 (35.5%) 763 (20.1%) 2.28 (1.73–3.01)
 Bipolar disorder 9 (3.3%) 27 (0.7%) 4.02 (1.87–8.64)
 Depression 130 (47.6%) 812 (21.4%) 3.92 (2.94–5.22)
 Eating disorders 12 (4.4%) 56 (1.5%) 3.22 (1.69–6.13)
 Personality disorders 11 (4.0%) 19 (0.5%) 8.32 (3.83-18.0)
 Schizophrenia-spectrum disorders 15 (5.5%) 74 (2.0%) 2.77 (1.56–4.95)
 Substance misuse 57 (20.9%) 207 (5.5%) 5.17 (3.61–7.41)
Charlson comorbidity index
 0 151 (55.3%) 2267 (59.8%) 1 (ref)
 1 66 (24.2%) 950 (25.1%) 1.07 (0.79–1.45)
 2 or 3 31 (11.4%) 425 (11.2%) 1.14 (0.75–1.74)
 4 or more 25 (9.1%) 148 (3.9%) 2.91 (1.75–4.82)
Table 4  AED utilization in cases and controls
Number of types of AEDs prescribed in the 90 days preceding self-
harm case date and evidence of treatment augmentation in the 6 
months prior to self-harm case date
AED utilization Cases (n = 273) Controls 
(n = 3790)
OR (95% CI)
Current number of AEDs
 0 43 (15.8%) 486 (12.8%) 1.47 (1.01–2.12)
 1 152 (55.6%) 2644 (69.8%) 1 (ref)
 2 56 (20.5%) 507 (13.4%) 1.84 (1.33–2.55)
 3 or more 22 (8.1%) 153 (4.0%) 2.44 (1.51–3.94)
Augmentation in prior 6 months
 0 202 (87.8%) 3588 (94.7%) 1 (ref)
 1 or more 28 (12.2%) 202 (5.3%) 2.12 (1.38–3.26)
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psychiatric referral, previous hospitalization for any reason, 
or five or more consultations with their GP in the previ-
ous year. Individuals treated with none or multiple AEDs, 
including those who had recently augmented treatment, were 
at increased risk of self-harm, compared to those prescribed 
AED monotherapy.
We report the first published estimates for elevated self-
harm risk in people with incident epilepsy in which self-
harm cases were ascertained using both primary and sec-
ondary care records. Our estimates are slightly higher than 
those reported in earlier studies that included only individu-
als who presented to hospital with self-harm [4, 5] and esti-
mates from the study using the predecessor to the CPRD, 
prior to linkage availability (OR 2.35, 95% CI 1.67–3.29), 
thus including only self-harm episodes that were recorded 
in primary care [6]. Previous studies did not restrict to an 
incident epilepsy cohort; therefore, inclusion of individuals 
with prevalent epilepsy may have resulted in prevalent-user 
bias [11]. This may have diluted the period of highest risk, 
close to the time of incident epilepsy diagnosis.
Among people with epilepsy, we found that elevated self-
harm risk was associated with prior diagnosis of any mental 
illness or referral to psychiatric services. This corroborates 
with evidence reported from general population studies 
in which mental illness is associated with a 6- to 14-fold 
increased risk of self-harm, dependent on the specific diag-
nosis [4]. Within the epilepsy cohort, a fivefold increased 
risk of self-harm was associated with history of alcohol and 
substance misuse. It is possible that these individuals experi-
ence a high frequency of seizures, caused by the alcohol or 
substance misuse, or due to non-compliance with treatment 
as a result of a disordered lifestyle. This could contribute to 
the increased self-harm risk experienced by these individu-
als. A bidirectional relationship between attempted suicide, 
which includes self-harm, and epilepsy has been suggested 
previously [25].
Having five or more face-to-face general practice con-
sultations in the previous year was associated with elevated 
self-harm risk, compared to people who attend up to four 
times per year. Clinicians should be alert to the risk of self-
harm in individuals who present regularly, which may be in 
relation to epilepsy severity or comorbid conditions. Impor-
tantly, clinicians can use these frequent interactions to dis-
cuss self-harm risk with patients in this group.
The use of multiple AEDs is a result of treatment aug-
mentation, due to inadequate seizure control; or during a 
period of switching to an alternative monotherapy due to 
lack of tolerance or for other reasons such as pregnancy 
[22]. The elevated self-harm risk observed during use of 
multiple AEDs is likely to be an indication of more severe 
epilepsy with an associated higher seizure frequency, which 
is not controlled by AED monotherapy. Furthermore, indi-
viduals who have many seizures may experience consequent 
psychosocial difficulties, including inability to drive or 
absence from work or social activities, which may exacer-
bate the stigma associated with epilepsy [26]. Additionally, 
some individuals may become despondent if AED treatment 
requires augmentation, despite compliance with mono-
therapy. This may result in difficulty coping and the condi-
tion may be perceived as a burden to the individual, both 
of which are known motivators of suicidal behaviour [27]. 
Indeed, we observed an elevated risk of self-harm associated 
with recent augmentation of AED treatment. We have previ-
ously identified the need to examine the risk associated with 
individual AEDs using carefully designed, new-user studies 
[28]. This was not the aim of this study; therefore, the study 
design does not allow us to comment on individual AEDs.
Self-harm risk was also elevated for people who were not 
prescribed an AED in the 90 days prior to the index self-
harm case date (OR 1.47, 95% CI 1.01–2.12). On entry to 
the incident epilepsy cohort, all individuals were prescribed 
an AED. Therefore, those individuals without AED prescrip-
tion on the self-harm case date may have gradually stopped 
taking AEDs because they became seizure free. In the UK, 
the National Institute for Health and Care Excellence (NICE) 
recommends that AED withdrawal should only be consid-
ered following a 2-year absence of seizures [21]. Given that 
the median time since epilepsy diagnosis on self-harm case 
date was approximately 2 years, it is unlikely that all of those 
who had no recent AED prescription withdrew their AED 
on the advice of a clinician. It is possible that some of those 
individuals were non-compliant with their medication regi-
men. This may be motivated by undesirable adverse events, 
beliefs about medication and illness, comorbid mental ill-
ness or lifestyle choices, all of which may potentially con-
tribute to elevated self-harm risk.
Healthcare professionals involved in the care of people 
with epilepsy could instigate conversations about self-harm 
risk, especially if the described risk factors are present. 
These include mental health problems, and extend to both 
the clinicians responsible for the mental health services and 
those working in general primary care settings. Furthermore, 
GPs should consider discussing self-harm risk management 
in people who consult frequently. Further research could 
investigate whether any technological prompts could aid this 
during consultations.
Strengths and limitations
This is the first published study to estimate self-harm risk 
among people with epilepsy in a large, linked primary care 
patient cohort, including 11,690 people with incident epi-
lepsy. Linkage to HES maximized self-harm case ascertain-
ment. The Read codes used to identify self-harm cases were 
verified by clinicians and have been used in other studies 
[15, 29]. To mitigate confounding by previous self-harm, 
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we restricted the incident epilepsy cohort to include only 
those persons with no prior recorded history of self-harm 
in either their primary or secondary healthcare records. It 
is still possible, however, that individuals had a self-harm 
event prior to this look-back period and before their CPRD 
records began. Furthermore, we recognize that not all peo-
ple who have a self-harm episode will present to healthcare 
services and those who do represent the “tip of the iceberg” 
of self-harm events [30]. However, our inclusion of self-
harm reported to both primary and secondary care builds 
upon those studies which used only one of those sources to 
ascertain self-harm [4–6]. As people with epilepsy attend 
the GP more often than those who do not, there may have 
been more opportunity to report self-harm and they may be 
asked about self-harm as per the WHO recommendations 
[7]. This would overestimate the magnitude of elevated self-
harm risk in people with epilepsy compared to those without 
the condition.
It is not possible to accurately determine the type of 
epilepsy from UK general practice data; therefore, this is 
something we could not examine in this study. Epilepsy type 
may influence risk of self-harm [31]. It would, therefore, be 
beneficial to compare self-harm risk among people with dif-
ferent epilepsy subtypes, particularly whether having symp-
tomatic epilepsy (and therefore underlying brain pathology) 
has an influence on self-harm risk.
Conclusion
In conclusion, clinicians should be aware that people with 
epilepsy are at increased risk of self-harm, compared to 
those without the condition, especially during the first year 
post-diagnosis. These patients should, therefore, be routinely 
monitored. Additionally, we recommend that clinicians are 
particularly vigilant for self-harm thoughts and behaviours 
in people with epilepsy and comorbid mental illness, those 
who consult regularly, those prescribed AED polytherapy 
and during periods of AED treatment augmentation.
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